News | April 29, 2025
Vimta Labs to invest Rs. 50 crores to Biologics CDMO business foray
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
The foray into this new segment will help Vimta to enter into the growing CDMO business of biologics and peptides
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Strengthening capabilities in Peptide Therapeutics and CDMO services
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
Investment includes biotech agreements with Harbour BioMed, Syneron Bio and BioKangtai
The acquisition aligns with Granules' vision to enter the rapidly expanding peptide-based anti-diabetic and anti-obesity market
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
The company plans to fund this Capex through debt and internal accruals and expects the project to be completed by FY27
Anthem’s business comprises of CRDMO services and the manufacture and sale of Specialty Ingredients
Subscribe To Our Newsletter & Stay Updated
